Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government.
Journal
Applied health economics and health policy
ISSN: 1179-1896
Titre abrégé: Appl Health Econ Health Policy
Pays: New Zealand
ID NLM: 101150314
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
accepted:
17
05
2023
medline:
7
11
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
ppublish
Résumé
Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it 'on label'. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs.
Identifiants
pubmed: 37398987
doi: 10.1007/s40258-023-00816-6
pii: 10.1007/s40258-023-00816-6
pmc: PMC10627937
doi:
Substances chimiques
Drugs, Generic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-840Informations de copyright
© 2023. The Author(s).
Références
https://pubmed.ncbi.nlm.nih.gov/?term=drug+repurposing&filter=datesearch.y_5 . Accessed 15 Aug 2022.
Janes J, Young ME, Chen E, Rogers NH, Burgstaller-Muehlbacher S, Hughes LD, et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc Natl Acad Sci USA. 2018;115(42):10750–5.
pubmed: 30282735
pmcid: 6196526
doi: 10.1073/pnas.1810137115
Ayoub BM, Michel HE, Mowaka S, Hendy MS, Tadros MM. Repurposing of omarigliptin as a neuroprotective agent based on docking with A2A adenosine and AChE receptors, brain GLP-1 response and its brain/plasma concentration ratio after 28 days multiple doses in rats using LC-MS/MS. Molecules. 2021;26(4):889.
pubmed: 33567615
pmcid: 7915074
doi: 10.3390/molecules26040889
Bellera CL, Balcazar DE, Alberca L, Labriola CA, Talevi A, Carrillo C. Identification of levothyroxine antichagasic activity through computer-aided drug repurposing. Sci World J. 2014;2014: 279618.
doi: 10.1155/2014/279618
Bouscary A, Quessada C, Mosbach A, Callizot N, Spedding M, Loeffler JP, et al. Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis. Front Pharmacol. 2019;10:883.
pubmed: 31447678
pmcid: 6692493
doi: 10.3389/fphar.2019.00883
Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K, et al. Novel agents for the pharmacological treatment of alcohol use disorder. Drugs. 2022;82(3):251–74.
pubmed: 35133639
pmcid: 8888464
doi: 10.1007/s40265-021-01670-3
Cao DW, Hou MX, Zhang XR. Ambroxol alleviates ventilator-induced lung injury by inhibiting c-Jun expression. Eur Rev Med Pharmacol Sci. 2019;23(11):5004–11.
pubmed: 31210340
Cotrina EY, Oliveira Â, Leite JP, Llop J, Gales L, Quintana J, et al. Repurposing benzbromarone for familial amyloid polyneuropathy: a new transthyretin tetramer stabilizer. Int J Mol Sci. 2020;21(19):7166.
pubmed: 32998442
pmcid: 7583827
doi: 10.3390/ijms21197166
Garcia R, Le T, Scott SN, Charmchi D, Sprout JML, Pentkowski NS, et al. Preclinical support for the therapeutic potential of zolmitriptan as a treatment for cocaine use disorders. Transl Psychiatry. 2020;10(1):266.
pubmed: 32747623
pmcid: 7398918
doi: 10.1038/s41398-020-00956-6
Jung YJ, Tweedie D, Scerba MT, Greig NH. Neuroinflammation as a factor of neurodegenerative disease: Thalidomide analogs as treatments. Front Cell Dev Biol. 2019;7:313.
pubmed: 31867326
pmcid: 6904283
doi: 10.3389/fcell.2019.00313
Kazemi Z, Bergmayr C, Prchal-Murphy M, Javaheri T, Themanns M, Pham HT, et al. Repurposing Treprostinil for enhancing hematopoietic progenitor cell transplantation. Mol Pharmacol. 2016;89(6):630–44.
pubmed: 26989084
pmcid: 4885501
doi: 10.1124/mol.116.103267
Klein P, Friedman A, Hameed MQ, Kaminski RM, Bar-Klein G, Klitgaard H, et al. Repurposed molecules for antiepileptogenesis: missing an opportunity to prevent epilepsy? Epilepsia. 2020;61(3):359–86.
pubmed: 32196665
pmcid: 8317585
doi: 10.1111/epi.16450
Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, et al. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018;103(7):1218–28.
pubmed: 29622655
pmcid: 6029548
doi: 10.3324/haematol.2017.174482
Layfield HJ, Williams HF, Ravishankar D, Mehmi A, Sonavane M, Salim A, et al. Repurposing cancer drugs batimastat and marimastat to inhibit the activity of a group i metalloprotease from the venom of the western diamondback rattlesnake, Crotalus atrox. Toxins. 2020;12(5):309.
pubmed: 32397419
pmcid: 7290494
doi: 10.3390/toxins12050309
Lee SY, Song MY, Kim D, Park C, Park DK, Kim DG, et al. A proteotranscriptomic-based computational drug-repositioning method for Alzheimer’s disease. Front Pharmacol. 2019;10:1653.
pubmed: 32063857
doi: 10.3389/fphar.2019.01653
Lin C-S, Huang S-H, Yan B-Y, Lai H-C, Lin C-W. Effective antiviral activity of the tyrosine kinase inhibitor sunitinib malate against Zika virus. Infect Chemother. 2021;53(4):730–40.
pubmed: 34951532
pmcid: 8731257
doi: 10.3947/ic.2021.0111
Palaniappan B, Solomon AP, David Raja C. Targeting AgrA quorum sensing regulator by bumetanide attenuates virulence in Staphylococcus aureus—a drug repurposing approach. Life Sci. 2021;273:119306.
pubmed: 33662434
doi: 10.1016/j.lfs.2021.119306
Paus R, Ramot Y, Kirsner RS, Tomic-Canic M. Topical L-thyroxine: the Cinderella among hormones waiting to dance on the floor of dermatological therapy? Exp Dermatol. 2020;29(9):910–23.
pubmed: 32682336
pmcid: 7722149
doi: 10.1111/exd.14156
Rausch M, Rutz A, Allard P-M, Delucinge-Vivier C, Docquier M, Dormond O, et al. Drug repurposing to identify a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma. Cancers. 2021;13(16):3978.
pubmed: 34439134
pmcid: 8391235
doi: 10.3390/cancers13163978
Ronca V, Carbone M, Bernuzzi F, Malinverno F, Mousa HS, Gershwin ME, et al. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. Expert Rev Clin Immunol. 2017;13(12):1121–31.
pubmed: 28994348
doi: 10.1080/1744666X.2017.1391093
Rossi SA, Oliveira HCD, Agreda-Mellon D, Lucio J, Mendes-Giannini MJS, García-Cambero JP, et al. Identification of off-patent drugs that show synergism with amphotericin B or that present antifungal action against Cryptococcus neoformans and Candida spp. Antimicrob Agents Chemother. 2020;64(4):e01921-e2019.
pubmed: 31988099
pmcid: 7179310
doi: 10.1128/AAC.01921-19
Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66(1):180–90.
pubmed: 27646933
doi: 10.1136/gutjnl-2016-312431
Ryan NM, Vertigan AE, Birring SS. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Expert Opin Pharmacother. 2018;19(7):687–711.
pubmed: 29658795
pmcid: 5935050
doi: 10.1080/14656566.2018.1462795
Sanz J, Lin D, Miteva M. Drugs targeting epithelial–mesenchymal transition molecules for treatment of lichen planopilaris. Clin Exp Dermatol. 2022;47(9):1642–9.
pubmed: 35506309
doi: 10.1111/ced.15245
Shimada T, Kadota K, Kubo S, Habara S, Mitsudo K. Coronary Intramural hematoma presenting as acute coronary syndrome. Intern Med. 2016;55(15):2025–9.
pubmed: 27477409
doi: 10.2169/internalmedicine.55.6652
Sillerud LO, Neuwelt AJ, Staquicini FI, Arap W, Pasqualini R. Repurposing ferumoxytol as a breast cancer-associated macrophage tracer with five-dimensional quantitative [Fe]MRI of SPION dynamics. Cancers. 2021;13(15):3802.
pubmed: 34359704
pmcid: 8345165
doi: 10.3390/cancers13153802
Thangaraju P, Kumar BA, Velmurugan H, Venkatesan S, SreeSudha T. Leprosy reactions: clinical pharmacologist perspective with repurposed medications. Infect Disord Drug Targ. 2022.
Thirumal Kumar D, Iyer S, Christy JP, Siva R, Tayubi IA, George Priya Doss C, et al. Chapter eight: A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease. In: Donev R, editor. Advances in protein chemistry and structural biology. Academic Press; 2019. p. 315–39.
Torrico TJ, Kaur S, Dayal M, Eagala P, Weinstein D. Lubiprostone for the treatment of clozapine-induced constipation: a case series. Cureus. 2022;14(6): e25576.
pubmed: 35785010
pmcid: 9249388
Tung M-C, Lin Y-W, Lee W-J, Wen Y-C, Liu Y-C, Chen J-Q, et al. Targeting DRD2 by the antipsychotic drug, penfluridol, retards growth of renal cell carcinoma via inducing stemness inhibition and autophagy-mediated apoptosis. Cell Death Dis. 2022;13(4):400.
pubmed: 35461314
pmcid: 9035181
doi: 10.1038/s41419-022-04828-3
2020 Generic Drug & Biosimilars Access & Savings in the U.S. Report. 2020. https://accessiblemeds.org/sites/default/files/2020-09/AAM-2020-Generics-Biosimilars-Access-Savings-Report-US-Web.pdf . Accessed 14 Oct 2022.
Novel Drug Approvals for 2021. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021 . Accessed 14 Oct 2022.
2021 First Generic Drug Approvals. https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2021-first-generic-drug-approvals . Accessed 14 Oct 2022.
Langedijk J, Whitehead CJ, Slijkerman DS, Leufkens HG, Schutjens MH, Mantel-Teeuwisse AK. Extensions of indication throughout the drug product lifecycle: a quantitative analysis. Drug Discov Today. 2016;21(2):348–55.
pubmed: 26657087
doi: 10.1016/j.drudis.2015.11.009
Workman P, Draetta GF, Schellens JHM, Bernards R. How much longer will we put up with $100,000 cancer drugs? Cell. 2017;168(4):579–83.
pubmed: 28187281
doi: 10.1016/j.cell.2017.01.034
Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe CC, Ferrario A, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328.
pubmed: 30568938
pmcid: 6290038
doi: 10.3389/fpubh.2018.00328
Verbaanderd C, Rooman I, Meheus L, Huys I. On-Label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients. Front Pharmacol. 2019;10:1664.
pubmed: 32076405
doi: 10.3389/fphar.2019.01664
Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov. 2019;18(1):1–2.
pubmed: 29880920
doi: 10.1038/nrd.2018.92
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.
pubmed: 30310233
doi: 10.1038/nrd.2018.168
Begley CG, Ashton M, Baell J, Bettess M, Brown MP, Carter B, et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci Transl Med. 2021;13(612):eabd5524.
pubmed: 34550729
doi: 10.1126/scitranslmed.abd5524
Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643–53.
pubmed: 34003459
pmcid: 8219567
doi: 10.1007/s40263-021-00825-w
IMI2 JU Scientific Committee recommendations regarding Drug Repurposing. https://www.imi.europa.eu/sites/default/files/SC_RecommendationDrug_Repurposing.pdf . Accessed 14 Oct 2022.
Drug repurposing. https://www.anticancerfund.org/en/drug-repurposing . Accessed 20 Apr 2023.
The RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2020;384(8):693–704.
WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed antiviral drugs for Covid-19—interim WHO Solidarity trial results. N Engl J Med. 2020;384(6):497–511.
Action grants for the Computer-aided Drug Repurposing for Cancer Therapy Project. 2021. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/eu4h-2021-pj-16;callCode=EU4H-2021-PJ2;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1;statusCodes=31094501,31094502,31094503;programmePeriod=null;programCcm2Id=null;programDivisionCode=null;focusAreaCode=null;destination=null;mission=null;geographicalZonesCode=null;programmeDivisionProspect=null;startDateLte=null;startDateGte=null;crossCuttingPriorityCode=null;cpvCode=null;performanceOfDelivery=null;sortQuery=sortStatus;orderBy=asc;onlyTenders=false;topicListKey=callTopicSearchTableState . Accessed 16 Aug 2022.
Juárez-López D, Schcolnik-Cabrera A. Drug repurposing: considerations to surpass while re-directing old compounds for new treatments. Arch Med Res. 2021;52(3):243–51.
pubmed: 33190955
doi: 10.1016/j.arcmed.2020.10.021
Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8(2):47–52.
pubmed: 8858389
Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85–94.
pubmed: 28089471
doi: 10.1016/S0140-6736(16)00645-0
Harbers VEM, Rongen G, van der Vleuten CJM, Verhoeven BH, de Laat PCJ, van der Horst C, et al. Patients with Congenital low-flow vascular malformation treated with low dose sirolimus. Adv Ther. 2021;38(6):3465–82.
pubmed: 34003452
pmcid: 8190005
doi: 10.1007/s12325-021-01758-y
Guilbert SM, Cardoso D, Lévy N, Muchir A, Nissan X. Hutchinson-Gilford progeria syndrome: rejuvenating old drugs to fight accelerated ageing. Methods. 2021;190:3–12.
pubmed: 32278808
doi: 10.1016/j.ymeth.2020.04.005
Vaiserman A, Koliada A, Lushchak O, Castillo MJ. Repurposing drugs to fight aging: The difficult path from bench to bedside. Med Res Rev. 2021;41(3):1676–700.
pubmed: 33314257
doi: 10.1002/med.21773
Spedding M, Marvaud R, Marck A, Delarochelambert Q, Toussaint JF. Aging, VO(2) max, entropy, and COVID-19. Indian J Pharmacol. 2022;54(1):58–62.
pubmed: 35343209
pmcid: 9012415
doi: 10.4103/ijp.ijp_442_21
Gegg ME, Menozzi E, Schapira AHV. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiol Dis. 2022;166: 105663.
pubmed: 35183702
doi: 10.1016/j.nbd.2022.105663
Magalhaes J, Gegg ME, Migdalska-Richards A, Schapira AH. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep. 2018;8(1):1385.
pubmed: 29362387
pmcid: 5780491
doi: 10.1038/s41598-018-19479-8
Mullin S, Smith L, Lee K, D’Souza G, Woodgate P, Elflein J, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77(4):427–34.
pubmed: 31930374
pmcid: 6990847
doi: 10.1001/jamaneurol.2019.4611
Bouscary A, Quessada C, René F, Spedding M, Henriques A, Ngo S, et al. Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases. Eur J Pharmacol. 2020;5(884): 173446.
doi: 10.1016/j.ejphar.2020.173446
Istaiti M, Revel-Vilk S, Becker-Cohen M, Dinur T, Ramaswami U, Castillo-Garcia D, Ceron-Rodriguez M, Chan A, Rodic P, Tincheva RS, Al-Hertani W, Lee BH, Yang CF, Kiec-Wilk B, Fiumara A, Rubio B, Zimran A (2021) Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. Am J Hematol. 2021;96(5):545–51. https://doi.org/10.1002/ajh.26131 .
Ambroxol for Parkinson’s: the story behind the medicine. 2023. Available from: https://cureparkinsons.org.uk/ambroxol-the-story-behind-the-medicine/. Accessed 20 Apr 2023.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.
pubmed: 32865380
doi: 10.1056/NEJMoa2021372
Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.
pubmed: 31733140
doi: 10.1056/NEJMoa1912388
Nidorf Stefan M, Eikelboom John W, Budgeon Charley A, Thompson Peter L. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10.
pubmed: 23265346
doi: 10.1016/j.jacc.2012.10.027
Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7(5):486–95.
pubmed: 32407460
doi: 10.1093/ehjqcco/qcaa045
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.
pubmed: 34458905
doi: 10.1093/eurheartj/ehab484
Horizon Europe. https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe_en . Accessed 16 Aug 2022.
Bloom BE. Creating new economic incentives for repurposing generic drugs for unsolved diseases using social finance. Assay Drug Dev Technol. 2015;13(10):606–11.
pubmed: 26284286
doi: 10.1089/adt.2015.29015.beddrrr
Asker-Hagelberg C, Boran T, Bouygues C, Eskola SM, Helmle L, Hernández C, et al. Repurposing of medicines in the EU: launch of a pilot framework. Front Med. 2022;8:2879.
doi: 10.3389/fmed.2021.817663
Repurposing of authorised medicines: Pilot to support not-for-profit organisations and academia. 2021. https://www.ema.europa.eu/en/news/repurposing-authorised-medicines-pilot-support-not-profit-organisations-academia . Accessed 8 Aug 2022.
Opportunities to Repurpose Medicines in the NHS in England. 2019. https://www.england.nhs.uk/wp-content/uploads/2021/03/B0342-oportunities-to-repurpose-medicines-in-the-nhs-in-england.pdf . Accessed 20 Apr 2023.
Prats-Uribe A, Sena AG, Lai LYH, Ahmed W-U-R, Alghoul H, Alser O, et al. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. BMJ. 2021;373:n1038.
Tummino TA, Rezelj VV, Fischer B, Fischer A, O’Meara MJ, Monel B, et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science. 2021;373(6554):541–7.
pubmed: 34326236
pmcid: 8501941
doi: 10.1126/science.abi4708
Glasziou PP, Sanders S, Hoffmann T. Waste in covid-19 research. BMJ. 2020;369:m1847.
pubmed: 32398241
doi: 10.1136/bmj.m1847